

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH GROUP INC.

(中國醫療集團有限公司)

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Formerly known as “Venturepharm Laboratories Limited”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

**(1) SUPPLEMENTAL ANNOUNCEMENT TO POSTPONEMENT OF BOARD MEETING
AND DELAY IN PUBLISHING THE 2018 ANNUAL RESULT ANNOUNCEMENT**

**(2) DELAY IN DESPATCH OF THE ANNUAL REPORT FOR
THE YEAR ENDED 31 DECEMBER 2018**

AND

(3) SUSPENSION OF TRADING

This announcement is made by China Health Group Inc. (the “Company”) pursuant to Rule 18.48A, Rule 18.49 and Rule 18.03 of the Rule Governing the Listing of Securities on GEM (the “Listing Rules”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)

Supplemental Announcement to Postponement of Board Meeting and Delay in Publishing the 2018 Annual Result Announcement

Reference is made to the announcement of the Company dated 22 March 2019 (the “Announcement”) in relation to the postponement of the meeting (the “Board Meeting”) of the board of directors of the Company (the “Board”). Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company hereby provides supplemental information in relation to the audit of the consolidated financial statements of the Company and its subsidiaries for the year ended 31 December 2018.

In accordance with Rule 18.49 of the Listing Rules, the Company must publish the 2018 Annual Result Announcement on or before 31 March 2019. Due to the replacement of auditors and the impact of the new accounting standards in Hong Kong, the Company will need more time to implement the full-year performance in 2018 with the new auditors.

The Company will make further announcement(s) as and when appropriate, to inform shareholders of the Company (the “Shareholders”) regarding the date of the Board Meeting and publication of 2018 Annual Result Announcement or any updated information.

Delay in Despatch of the Annual Report for the Year Ended 31 December 2018

Pursuant to Rule 18.48A and 18.03 of the Listing Rules, the Company must send a copy of the annual report for the year ended 31 December 2018 (the “2018 AR”) to its shareholders not more than 3 months after the date upon which the financial year ended (i.e. by 31 March 2019). Due to delay in publication of the 2018 Annual Result Announcement, the 2018 AR will also be delayed in despatch. The Company expects that the 2018 AR will be despatched immediately after the publication of the 2018 Annual Result Announcement. The Company will make further announcement(s) to inform the Shareholders about the despatch date of the 2018 AR.

The Board is aware that delay in publication of the 2018 Annual Result Announcement and delay in despatch the 2018 AR will cause non-compliance with the requirements under the Rule 18.49 and Rule 18.03 of the Listing Rules, respectively, and strives to publish the 2018 Annual Result Announcement and despatch the 2018 AR as soon as possible. The Company will make further announcement(s) in due course to inform the Shareholders about the relevant meeting of the Board as well as the publication date of the 2018 Annual Result Announcement, despatch date of the 2018 AR and any other material information.

Suspension of Trading

At the request of the Company, trading in the shares of the Company (stock code: 08225) was halted on the Stock Exchange since 9:00 a.m. on 1 April 2019 pending the publication of the 2018 Annual Result Announcement.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
China Health Group Inc.
William Xia GUO
Chairman

Hong Kong, 1 April 2019

As at the date hereof, the Board comprises two executive directors, being Mr. William Xia GUO and Dr. Maria Xue Mei SONG; one non-executive director, being Mr. Michael SU; and four independent non-executive directors, being Mr. Rui QIU, Mr. Mark Gavin LOTTER, Dr. Bin Hui NI and Mr. Ling ZHEN.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the Company’s website at www.chgi.net.